Capítulo 3: Manejo de los lípidos en la enfermedad renal crónica
DOI:
https://doi.org/10.47196/diab.v58i2Sup.785Palabras clave:
enfermedad renal crónica, diabetes mellitus, perfil lipídicoResumen
La coexistencia de enfermedad renal crónica (ERC) y diabetes mellitus (DM) actúa en forma sinérgica agravando las consecuencias renales y CV. La evaluación temprana del perfil lipídico permitirá establecer estrategias de tratamiento para disminuir la morbimortalidad por causas CV ateroscleróticas. El patrón lipídico característico de la ERC asociada a DM consiste, principalmente, en hipertrigliceridemia y disminución de los valores de colesterol-HDL (c-HDL). El incremento del nivel de triglicéridos es resultante de mecanismos fisiopatológicos que concurren en ambas patologías: sobreproducción hepática de VLDL, consecuencia de la insulinorresistencia y reducción de la lipólisis de los triglicéridos por disminución de la actividad de la enzima lipoproteína lipasa. La acumulación de los remanentes lipoproteicos constituye un significativo predictor de eventos CV.
Citas
I. Nguyen SV, Nakamura T, Uematsu M, et al. Remnant lipoproteinemia predicts cardiovascular events in patients with type 2 diabetes and chronic kidney disease. J Cardiol. 2017;69(3):529-535. doi:10.1016/j.jjcc.2016.04.011.
II. Ferro CJ, Mark PB, Kanbay M, et al. Lipid management in patients with chronic kidney disease [published correction appears in Nat Rev Nephrol. 2019 Feb;15(2):121]. Nat Rev Nephrol. 2018;14(12):727-749. doi:10.1038/s41581-018-0072-9.
III. Luo D, Luo Y, Zou Y, et al. Non-high-density lipoprotein cholesterol may predict the cardio-cerebrovascular risk in patients on maintenance hemodialysis. Lipids Health Dis 2021;20(1):159. doi:10.1186/s12944-021-01546-1.
IV. Lamprea-Montealegre JA, Staplin N, Herrington WG, et al. Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD. Clin J Am Soc Nephrol 2020;15(1):47-60. doi:10.2215/CJN.07320619.
V. Barbagallo CM, Cefalù AB, Giammanco A, et al. Lipoprotein abnormalities in chronic kidney disease and renal transplantation. Life (Basel) 2021;11(4):315. doi:10.3390/life11040315.
VI. Hopewell JC, Haynes R, Baigent C. The role of lipoprotein (a) in chronic kidney disease. J Lipid Res. 2018;59(4):577-585. doi:10.1194/jlr.R083626.
VII. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013;382(9889):339-352. doi:10.1016/S0140-6736(13)60595-4.
VIII. Colantonio LD, Baber U, Banach M, et al. Contrasting cholesterol management guidelines for adults with CKD. J Am Soc Nephrol 2015;26(5):1173-1180. doi:10.1681/ASN.2014040400.
IX. Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk [published correction appears in Atherosclerosis. 2020 Jan;292:160-162] [published correction appears in Atherosclerosis. 2020 Feb;294:80-82]. Atherosclerosis 2019;290:140-205. doi:10.1016/j.atherosclerosis.2019.08.014.
X. Pontremoli R, Bellizzi V, Bianchi S, et al. Management of dyslipidaemia in patients with chronic kidney disease: a position paper endorsed by the Italian Society of Nephrology. J Nephrol 2020;33(3):417-430. doi:10.1007/s40620-020-00707-2.
XI. Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation 2021;143(11):1157-1172. doi:10.1161/CIRCULATIONAHA.120.050686.
XII. Mori H, Torii S, Kutyna M, Sakamoto A, Finn AV, Virmani R. Coronary artery calcification and its progression: what does it really mean? JACC Cardiovasc Imaging 2018;11(1):127-142. doi:10.1016/j.jcmg.2017.10.012.
XIII. Palmer SC, Navaneethan SD, Craig JC, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2014;(5):CD007784. doi: 10.1002/14651858.CD007784.pub2.
XIV. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA 2004;291(7):844-850. doi:10.1001/jama.291.7.844.
XV. Xu Y, Liu B, Lin L, et al. The association of apolipoprotein B with chronic kidney disease in the Chinese population. Front Endocrinol (Lausanne) 2023;14:1083614. doi:10.3389/fendo.2023.1083614.
XVI. Yun HR, Kim H, Park JT, et al. Obesity, metabolic abnormality, and progression of CKD. Am J Kidney Dis 2018;72(3):400-410. doi:10.1053/j.ajkd.2018.02.362.
XVII. Wu T, Ye J, Shao C, et al. Varied relationship of lipid and lipoprotein profiles to liver fat content in phenotypes of metabolic associated fatty liver disease. Front Endocrinol (Lausanne) 2021;12:691556. doi:10.3389/fendo.2021.691556.
XVIII. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377(9784):2181-2192. doi:10.1016/S0140-6736(11)60739-3.
XIX. Quiroga B, Ramos PM, Chiva VÁ. Efficacy and safety of the PCSK9 inhibitors in the treatment of dyslipidemia in chronic kidney disease. Nefrol 2020;40:499–505. doi: 10.1016/j.nefroe.2020.11.004.
XX. Wright RS, Collins MG, Stoekenbroek RM, et al. Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 Studies. Mayo Clin Proc 2020;95(1):77-89. doi:10.1016/j.mayocp.2019.08.021.
XXI. Nicholls S, Lincoff AM, Bays HE, Cho L, Grobbee DE, Kastelein JJ, et al. Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. Am Heart J 2021;235:104-112.
XXII. Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: The CLEAR Wisdom randomized clinical trial. JAMA 2019;322:1780-1788.
XXIII. Nissen SE, Lincoff AM, Brennan D, et al.; CLEAR Outcomes Investigators. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med 2023;388(15):1353-1364. doi: 10.1056/NEJMoa2215024.
XXIV. Majithia A, Bhatt DL, Friedman AN, et al. Benefits of icosapent ethyl across the range of kidney function in patients with established vardiovascular disease or diabetes: REDUCE-IT RENAL. Circulation 2021;144(22):1750-1759. doi:10.1161/CIRCULATIONAHA.121.055560.
XXV. Jun M, Zhu B, Tonelli M, et al. Effects of fibrates in kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol 2012;60(20):2061-2071. doi:10.1016/j.jacc.2012.07.049.
XXVI. Katsiki N, Mikhailidis DP, Banach M. Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease. Expert Opin Pharmacother 2019;20(16):2007-2017. doi:10.1080/14656566.2019.1649394.
XXVII. Rosenstein K, Tannock LR. Dyslipidemia in chronic kidney disease. In: Feingold KR, Anawalt B, Blackman MR, et al., eds. Endotext. South Dartmouth (MA): MDText.com, Inc.; February 10, 2022. PMID: 26247091.
XXVIII. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update [published correction appears in Am J Kidney Dis. 2013 Jun;61(6):1049]. Am J Kidney Dis. 2012;60(5):850-886. doi:10.1053/j.ajkd.2012.07.005
XXIX. Shepherd J, Kastelein JJ, Bittner V, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 2008;51(15):1448-1454. doi:10.1016/j.jacc.2007.11.072.
XXX. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377(9784):2181-2192. doi:10.1016/S0140-6736(11)60739-3.
XXXI. Shin JI, Fine DM, Sang Y, et al. Association of rosuvastatin use with risk of hematuria and proteinuria. J Am Soc Nephrol 2022;33(9):1767-1777. doi:10.1681/ASN.2022020135.
XXXII. Wanner C, Tonelli M; Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014;85(6):1303-1309. doi:10.1038/ki.2014.31.
XXXIII. Lee M, Choi WJ, Lee Y, Lee K, et al. Association between statin therapy and mortality in patients on dialysis after atherosclerotic cardiovascular diseases. Scientific reports 2023;13(1):10940. doi: 10.1038/s41598-023-37819-1.
XXXIV. Lee M, Hong YA, Myong JP, Lee K, Park MW, Kim DW. Trends and outcome of statin therapy in dialysis patients with atherosclerotic cardiovascular diseases: a population-based cohort study. PloS one 2023; 18(6):e0286670. doi: 10.1371/journal.pone.0286670.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2024 a nombre de los autores. Derechos de reproducción: Sociedad Argentina de Diabetes
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
